Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the ...

Catherine Laborde, who presented weather on TF1 in France for nearly 30 years, has died. Laborde passed away on Tuesday, Jan. 28 following a years-long battle with Lewy Body Dementia (LBD), which she ...

One of the most common early signs of dementia is short-term memory loss—as is forgetting important dates or events, ...

CervoMed Inc. announced that it will present topline results from its Phase 2b RewinD-LB study at the 8th International Lewy Body Dementia Conference in Amsterdam on January 31, 2025. The study ...

Cognition Therapeutics, Inc. announced promising results from the SHIMMER study of zervimesine (CT1812) in patients with mild-to-moderate dementia with Lewy bodies (DLB), to be presented by Dr ...

CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...

Cognition Therapeutics (CGTX) announced that JamesGalvin, MD, MPH will present topline results from the ‘SHIMMER’ study of zervimesine in ...

A number of blood tests have shown promise in research studies but aren’t routinely used in diagnosing dementia.

Two Fountain Hills women are working to make their town "dementia friendly" so that other caretakers know that they are not ...

Among patients with iRBD, altered visuospatial cue-elicited N2 and P3 ERPs predicted phenoconversion to α-synucleinopathies.